Key points are not available for this paper at this time.
This JAMA Forum discusses pending legislation in the US House and Senate and the history of the “firm-based approach” the US Food and Drug Administration (FDA) could use when regulating artificial intelligence (AI) medical devices to augment patient care.
Scott Gottlieb (Thu,) studied this question.